A tumor that acts more like a stubborn weed than a cancer
Giant cell tumors of bone are not traditional cancers. They are rare tumors — most often found in the long bones near the knee — that tend not to spread to other organs but are notorious for growing back after surgery.
Surgeons have two main options: curettage (scraping out the tumor and preserving the bone) or more extensive removal. Both carry meaningful risks of the tumor returning.
Why denosumab entered the picture
Denosumab (deh-NOH-sue-mab) is a drug originally approved to treat bone loss in osteoporosis and cancer-related bone disease. It works by blocking a protein called RANK-L, which giant cell tumors depend on for growth. Think of RANK-L as the fuel line for these tumors — denosumab clamps it shut.
In theory, giving denosumab before surgery should shrink the tumor, making the operation safer and simpler. It quickly became common practice in hospitals treating this disease.
But here's the catch: some doctors noticed that tumors seemed to come back more often in patients who had received denosumab. Others did not see that pattern. The evidence pulled in two directions, and no single study was large enough to settle the debate.
Pooling 16 studies to find an answer
This meta-analysis — a method of statistically combining results from multiple studies to find a more reliable answer — gathered data from 15 separate research groups, totaling 1,551 patients.
Of those patients, 310 received denosumab as part of their treatment, while 1,241 underwent surgery without it. Both groups had a mean age of 32 years. Researchers tracked local recurrence rates and drug-related side effects across all studies.
The timing turned out to be everything
Overall, patients who received denosumab had an 82% higher odds of local recurrence compared to those who did not — a statistically significant finding. When looking only at patients who had curettage (the more conservative surgery), the odds of recurrence were 2.75 times higher in the denosumab group.
But the story became much more specific when researchers looked at timing. Patients who received denosumab only before surgery showed no statistically significant increase in recurrence risk. The dramatic increase in risk came almost entirely from patients who received denosumab both before and after surgery — in that group, the odds of recurrence were more than five times higher than in patients who had no denosumab at all.
That finding does not mean denosumab is the wrong drug — it means the way it is being used may need to change.
Why postoperative use may backfire
One possible explanation involves how denosumab changes the tumor's biology. By blocking RANK-L, the drug causes giant cell tumors to convert into a more bone-like tissue — a process called ossification. This makes the tumor appear more controlled on imaging.
But some researchers suspect that postoperative denosumab may interfere with the body's natural wound-healing and immune surveillance processes in the surgical site, potentially creating conditions that favor regrowth. This remains a hypothesis, not a confirmed mechanism, but it is an active area of investigation.
If you or someone in your family has been diagnosed with a giant cell tumor of bone, this research is directly relevant to your treatment discussion. Ask your orthopedic oncologist specifically about the timing of any planned denosumab treatment — whether it is intended before surgery, after surgery, or both — and what the evidence shows for your specific surgical approach.
The 6.5% rate of denosumab-related complications reported across studies is also worth discussing with your care team before agreeing to the drug.
Limits worth knowing
This was a meta-analysis of observational studies, not a randomized controlled trial. That means patients were not randomly assigned to receive denosumab or not — which can introduce bias if patients who received denosumab had more complex or advanced tumors to begin with. Follow-up times also differed between groups (40 months for the denosumab group versus 62 months for controls), which may have affected recurrence detection.
These findings are likely to prompt updated clinical guidelines for giant cell tumor treatment. Researchers are calling for prospective randomized trials — studies where patients are assigned to treatment groups by chance — to confirm the timing effect and identify which patients might still benefit from postoperative denosumab despite the apparent risks. Until then, surgical teams treating giant cell tumors will need to weigh this new evidence carefully against each patient's individual circumstances.
